3 completed. 3 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Completed 3 |
| Phase 2 | 1 | Completed 1 |
Follow GV1001 peptide: new trials by email Literature Review of GV1001 peptide trials Research Report on GV1001 peptide
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluation of the Safety, Tolerability and PK Characteristics of GV1001 in Healthy Subjects GV1001, Placebo - Neuro-Degenerative Disease | Phase 1 | Completed | GemVax & Kael | 59 | 2024-10-08 | 2025-11-19 |
| A Study, Combination, Immunologic Study of LTX-315 as Adjunct to GV1001 in Patients Following Curative Surgery for Carcinoma LTX-315 - Carcinoma | Phase 1 | Completed | Lytix Biopharma AS | 12 | 2010-08-01 | 2012-01-11 |
| Trial With Telomerase Peptide Vaccine In Combination With Temozolomide in Patients With Advanced Malignant Melanoma GV1001 - Malignant Melanoma | Phase 1 / Phase 2 | Completed | Oslo University Hospital | 2005-01-01 | 2014-11-05 |
Carcinoma (1) · Melanoma (1) · Neoplasms (1)
GemVax & Kael (1) · Lytix Biopharma AS (1) · Oslo University Hospital (1)
Norway (2) · South Korea (1)